help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-2109
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chia, C. W.
Right arrow Articles by Egan, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chia, C. W.
Right arrow Articles by Egan, J. M.
Related Collections
Right arrow Diabetes and Insulin
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 10 3703-3716
Copyright © 2008 by The Endocrine Society


CLINICAL REVIEW

Incretin-Based Therapies in Type 2 Diabetes Mellitus

Chee W. Chia and Josephine M. Egan

National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224-6825

Context: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide are incretins secreted from enteroendocrine cells postprandially in part to regulate glucose homeostasis. Dysregulation of these hormones is evident in type 2 diabetes mellitus (T2DM). Two new drugs, exenatide (GLP-1 mimetic) and sitagliptin [dipeptidyl peptidase (DPP) 4 inhibitor], have been approved by regulatory agencies for treating T2DM. Liraglutide (GLP-1 mimetic) and vildagliptin (DPP 4 inhibitor) are expected to arrive on the market soon.

Evidence Acquisition: The background of incretin-based therapy and selected clinical trials of these four drugs are reviewed. A MEDLINE search was conducted for published articles using the key words incretin, glucose-dependent insulinotropic polypeptide, GLP-1, exendin-4, exenatide, DPP 4, liraglutide, sitagliptin, and vildagliptin.

Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year follow-up data on exenatide showed a sustained weight loss and glycosylated hemoglobin (HbA1c) reduction of 1%. Nausea and vomiting are common. Results from phase 3 studies are pending on liraglutide. Sitagliptin and vildagliptin are orally active. In 24-wk studies, sitagliptin reduces HbA1c by 0.6–0.8% as monotherapy, 1.8% as initial combination therapy with metformin, and 0.7% as add-on therapy to metformin. Vildagliptin monotherapy lowered HbA1c by 1.0–1.4% after 24 wk. Their major side effects are urinary tract and nasopharyngeal infections and headaches. Exenatide and liraglutide cause weight loss, whereas sitagliptin and vildagliptin do not.

Conclusions: The availability of GLP-1 mimetics and DPP 4 inhibitors has increased our armamentarium for treating T2DM. Unresolved issues such as the effects of GLP-1 mimetics and DPP 4 inhibitors on β-cell mass, the mechanism by which GLP-1 mimetics lowers glucagon levels, and exactly how DPP 4 inhibitors lead to a decline in plasma glucose levels without an increase in insulin secretion, need further research.




This article has been cited by other articles:


Home page
cfpHome page
S. A. Ross and J.-M. Ekoe
Incretin agents in type 2 diabetes
Can Fam Physician, July 1, 2010; 56(7): 639 - 648.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
J. Pinkney
Bariatric surgery for diabetes: gastric banding is simple and safe
The British Journal of Diabetes & Vascular Disease, May 1, 2010; 10(3): 139 - 142.
[Abstract] [PDF]


Home page
JRSMHome page
M. A. Karamat, A. Syed, and W. Hanif
Review of diabetes management and guidelines during Ramadan
J R Soc Med, April 1, 2010; 103(4): 139 - 147.
[Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
S. N. Murthy, R. C. S. Hilaire, D. B. Casey, A. M. Badejo, J. McGee, D. B. McNamara, P. J. Kadowitz, and V. A. Fonseca
The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
Diabetes and Vascular Disease Research, April 1, 2010; 7(2): 138 - 144.
[Abstract] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
K. E. Nori Janosz, K. C. Zalesin, W. M. Miller, and P. A. McCullough
Treating type 2 diabetes: incretin mimetics and enhancers
Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 387 - 395.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Moritoh, K. Takeuchi, and M. Hazama
Chronic Administration of Voglibose, an {alpha}-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 669 - 676.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
S. H Song and T. A Gray
Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008
The British Journal of Diabetes & Vascular Disease, March 1, 2009; 9(2): 69 - 74.
[Abstract] [PDF]


Home page
Pharmacol. Rev.Home page
W. Kim and J. M. Egan
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society